Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Dirnhofer

Showing results (151-160 of 155) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 155 results.
Nature|July 19, 2019
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasionAnna M Paczulla, Kathrin Rothfelder, Simon Raffel, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 17, 2013
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOPAlexandar Tzankov, Zijun Y Xu-Monette, Marc Gerhard, et al.
Life Science Alliance|June 25, 2020
EBV renders B cells susceptible to HIV-1 in humanized miceDonal McHugh, Renier Myburgh, Nicole Caduff, et al.
Blood|December 1, 2010
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcomeAndrea Rinaldi, Michael Mian, Ekaterina Chigrinova, et al.
Haematologica|August 30, 2012
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program StudyCarlo Visco, Alexander Tzankov, Zijun Y Xu-Monette, et al.
Pageof 16

Showing results (151-160 of 155) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 155 results.
Nature|July 19, 2019
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasionAnna M Paczulla, Kathrin Rothfelder, Simon Raffel, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 17, 2013
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOPAlexandar Tzankov, Zijun Y Xu-Monette, Marc Gerhard, et al.
Life Science Alliance|June 25, 2020
EBV renders B cells susceptible to HIV-1 in humanized miceDonal McHugh, Renier Myburgh, Nicole Caduff, et al.
Blood|December 1, 2010
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcomeAndrea Rinaldi, Michael Mian, Ekaterina Chigrinova, et al.
Haematologica|August 30, 2012
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program StudyCarlo Visco, Alexander Tzankov, Zijun Y Xu-Monette, et al.
Pageof 16